A new study of patients who have a normal stress test using the cardiac radiopharmaceutical Cardiolite (a kit for the preparation of technetium Tc99m sestamibi for injection) has shown an excellent prognosis for cardiac-event-free survival. Such patients may not require further invasive testing for heart disease, according to findings presented last week at the 52nd Annual Scientific Session of the American College of Cardiology in Chicago.
The study, performed at the State University of New York, Stony Brook, analyzed results in African-American, Hispanic, and Caucasian patients who had normal Cardiolite stress test results. The researchers found that the risk of a heart attack or sudden cardiac death within one year of having the test was equally low -- less than 1% -- for each group.
Statistical analysis demonstrated that a normal stress test with the product worked equally well in predicting cardiac events regardless of race, according to Cardiolite’s manufacturer, Bristol Myers Squibb Medical Imaging of North Billerica, MA.
By AuntMinnie.com staff writersApril 10, 2003
Related Reading
Cardiolite helps find early-stage CAD in diabetics, October 3, 2002
Bristol-Myers Squibb appoints imaging chief, July 31, 2002
Bristol-Myers-Squibb, Amersham Health share patent rights, November 15, 2001
Bristol-Myers Squibb completes DuPont purchase, October 4, 2001
Copyright © 2003 AuntMinnie.com
